Exact Sciences expects FY18 revenue of $454M-$455M, consensus $438.39M
Exact Sciences expects to report Q4 revenue between $142.5M-$143.5M, an increase of 64% percent from the same quarter of 2017. Consensus at $126.98M. The company completed approximately 292,000 Cologuard tests during the fourth quarter of 2018, which represents 66% growth from the same period of 2017. For full-year 2018, the company anticipates reporting total revenue between $454M-$455M, a year-over-year increase of 71%. Consensus at $438.39M. Completed Cologuard test volume during 2018 was approximately 934,000 tests, a 64% increase from 2017. Nearly 15,000 health care providers ordered Cologuard for the first time during the fourth quarter of 2018. The number of providers who have ordered Cologuard since its launch increased to nearly 147,000 during 2018. Exact Sciences has not completed preparation of its financial statements for Q4 or FY18. The company plans to report 2018 financial results and provide guidance during its February 2019 earnings call.